Semaglutide: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AWMSG (Wales), G-BA (Germany) and HIRA (South Korea), among others, recommended or restricted semaglutide, while CONITEC (Brazil) did not recommend it.
HAS (France) has been harder on semaglutide than on its own caseload: it refused 4 of 7 decisive submissions here (57%), against a base rate of 11% across everything it has assessed.
Assessment has run over 7.8 years, from 8 Aug 2018 at ZIN (Netherlands) to 8 Jun 2026 at SMC (Scotland).
HAS (France) changed its position: not recommended on 20 Feb 2019, recommended by 4 Feb 2026, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for semaglutide.
Not every gap is a refusal: for semaglutide, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 28 of 53 records date from 2023 or later.
The programme is broad: 15 distinct indication wordings are recorded for semaglutide by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
7 of these 53 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
ZIN (Netherlands) was first to assess semaglutide, on 8 Aug 2018; PHARMAC (New Zealand) did not open a file until 11 Dec 2025 — a wide spread of 7.3 years between the earliest and latest system to look at it.
The record arrives in waves: 9 separate years each carry two or more decisions, spread across 9 years in total.
11 of the 14 agencies here assessed semaglutide more than once, CIPM (Spain) most often at 9 entries — repeat review is the norm for this molecule rather than the exception.
semaglutide has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for semaglutide reads 21 recommended, 15 not recommended, 9 restricted and 3 appraised, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 21 May 2026 | Ozempic reimbursement recommendation | not recommended | source |
| NICE (England) | 7 May 2026 | NICE TA1152 | published appraisal | source |
| PHARMAC (New Zealand) | 7 Apr 2026 | Type II diabetes mellitus, insufficiently controlled | PTAC advice: High | source |
| HAS (France) | 4 Feb 2026 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| TLV (Sweden) | 28 Aug 2020 | Rybelsus ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
48 further decisions for semaglutide, across 14 agencies, are not shown here. They include the most recent record on file, 8 Jun 2026 from SMC (Scotland); its outcome is in the subscriber dataset. They link to 34 further source documents.
Related molecules
- tirzepatide — divergent outcome (recommended vs not recommended) on a shared indication
- exenatide — divergent outcome (recommended vs not recommended) on a shared indication
- liraglutide — divergent outcome (recommended vs not recommended) on a shared indication
- bupropion / naltrexone — divergent outcome (recommended vs not recommended) on a shared indication
- empagliflozin — same ATC class A10B — Diabetes
- dapagliflozin — same ATC class A10B — Diabetes
Coverage: 53 decisions for semaglutide from 14 agencies, 2018 to 2026. Data to 7 Sep 2026. ATC class A10B — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.